In a shocking turn of events, Bayer, through its controversial Monsanto division, has filed a lawsuit against major COVID-19 vaccine producers Pfizer, BioNTech, Moderna, and Johnson & Johnson. This ...

A roundup of the press releases sent via PR Newswire that received the most attention over the past year.NEW YORK, Jan. 9, ...

Many investors were giving cryptocurrencies and related assets the cold shoulder over the past few days. Bitmine couldn't buck that trend, as it's a top holder of Ethereum. Bitmine is essentially a ...

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

Shares of SoFi Technologies Inc. sank more than 6% in after-hours trading Thursday, after the fintech company announced plans for a $1.5 billion stock offering. In a statement, San Francisco-based ...

SAN FRANCISCO, Nov 13 - ChatGPT maker OpenAI on Thursday said it will invest in a startup focused on blocking bad actors from creating biological weapons powered by artificial intelligence. OpenAI is ...

The company raised full year MRD revenue guidance to a range of $202 million to $207 million, up from the prior $190 million to $200 million, citing "stronger-than-expected clinical revenue ...

Tyler Technologies remains a sell, due to weak fundamentals and an unjustifiably high valuation, despite recent share price declines. TYL's top-line growth is decelerating, with bookings and ARR ...

The Food and Drug Administration is relaxing regulations on biosimilar drugs used for cancer and rare diseases in the hopes of boosting competition and lowering prices for high-cost pharmaceuticals.

This week's episode of "The Top Line" features a discussion about what’s working now in biotech and what isn't. Recorded Oct. 7 at Fierce Biotech Week, this panel featuring leaders from past Fierce 15 ...

Each of these stocks has grown briskly in the recent past. They have lots of potential for continued growth, though a few potential headwinds exist, too. 10 stocks we like better than Opendoor ...